Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.

Patients with asthma frequently have comorbid chronic rhinosinusitis (CRS) with or without nasal polyps, increasing disease burden and complicating treatment. These post hoc analyses investigated disease-specific health-related quality of life (HRQoL) and general health status in the randomized, placebo-controlled QUEST study (NCT02414854) in patients treated with dupilumab for moderate-to-severe asthma with comorbid CRS. Patients received 300 mg of dupilumab or placebo every 2 weeks for 52 weeks. CRS HRQoL was assessed by the 22-item Sino-Nasal Outcome Test (SNOT-22; items scored 0-5). The 22 items are categorized into 5 domains (nasal, ear/facial, sleep, function, and emotion), and patients report the top 5 most important items affecting their health. General health status was assessed by Euro-QoL visual analog scale (EQ-VAS). Of 1902 patients, 382 (20.1%) self-reported comorbid CRS; 193 patients receiving dupilumab 300 mg q2w or matched placebo were included in this analysis. At baseline, the most impacted SNOT-22 domain was nasal, and general health status was below population norms. Patients rated "decreased sense of taste/smell," "nasal blockage," "cough," "reduced productivity," and "wake up tired" as the 5 most important SNOT-22 items affecting their health. Percentage change from baseline in SNOT-22 total score was significantly greater for dupilumab vs placebo at Weeks 24, 36, and 52 (all p < 0.05). Improvements from baseline were significantly greater for dupilumab vs placebo at Week 52 for all SNOT-22 domains ( p < 0.05), except emotion. At Week 52, significant changes from baseline with dupilumab vs placebo were observed for all 5 most important SNOT-22 items affecting their health (all p < 0.05). EQ-VAS was significantly improved with dupilumab vs placebo by Week 12, with improvements sustained to Week 52 (all p < 0.01). In patients with moderate-to-severe asthma who self-reported comorbid CRS, dupilumab treatment vs placebo improved CRS-specific HRQoL and general health status.
Competing Interests: C.H. reports advisory board fees from AstraZeneca, Dianosic, GlaxoSmithKline, and Sanofi. K.M.B. reports advisory board fees from AstraZeneca, GlaxoSmithKline, Regeneron, and Sanofi. E.H. reports research grants from AstraZeneca, Boehringer Ingelheim, Circassia, GlaxoSmithKline, Nestlé Purina, Novartis, Sanofi, Stallergenes-Greer, Regeneron, Teva, and Valeas. N.A.C. reports consultancy from Novartis, Oysterpoint Pharmaceuticals, and Sanofi/Regeneron, as well as licensing agreement with GeneOne Life Sciences. H.O. reports research funds from AstraZeneca GmbH, GlaxoSmithKline GmbH & Co. KG, and F. Hoffmann-La Roche Ltd, as well as advisory board fees and lecture fees from Novartis Pharma GmbH and Sanofi-Aventis Deutschland GmbH. A.H.K., J.M, J.A.J.-N., P.J.R. are employees and may hold stock and/or stock options in Sanofi. S.S, S.N., Y.D. are employees and may hold stock and/or stock options in Regeneron Pharmaceuticals, Inc. The authors report no other conflicts of interest in this work.
(© 2022 Hopkins et al.)